Rituximab 500

Rituximab 500 mg Injection
Rituximab 500 mg Injection is a chimeric monoclonal antibody indicated for the treatment of CD20-positive B-cell malignancies and certain autoimmune disorders. It selectively targets the CD20 antigen on B-lymphocytes, leading to their depletion through immune-mediated mechanisms. Rituximab 500 mg is widely used in hematology and immunology treatment protocols worldwide.
Product Details
Generic Name: Rituximab
Strength: 500 mg
Dosage Form: Injection (Sterile concentrate for solution for infusion)
Route of Administration: Intravenous (IV infusion)
Therapeutic Class: Monoclonal Antibody / Targeted Anticancer Agent
Indications
Rituximab 500 mg Injection is indicated for:
Non-Hodgkin’s lymphoma (CD20-positive)
Chronic lymphocytic leukemia (CLL)
Rheumatoid arthritis (in combination with methotrexate)
Other CD20-positive B-cell disorders as prescribed
Mechanism of Action
Rituximab binds to the CD20 antigen present on B-lymphocytes and induces cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in effective B-cell depletion.
Key Benefits
Targeted action against CD20-positive B-cells
Proven efficacy in hematological malignancies
Can be used as monotherapy or in combination regimens
Widely accepted in global oncology and immunology guidelines
Dosage & Administration
Dosage and infusion schedule are determined by the treating physician based on indication, patient body surface area, and treatment protocol. Administration should be performed only under strict medical supervision.
Storage Conditions
Store at 2°C to 8°C (Refrigerated)
Do not freeze
Protect from light
Precautions
For hospital and oncology center use only
Premedication may be required to reduce infusion-related reactions
Monitor patients during and after infusion
Use with caution in patients with active infections